Stock Forecast

  Quantum Genomics Société Anonyme ( ALQGC.PA) Stock. Should you Buy or Sell?    $ 3.08

-0.01 (-0.33 %)

Quantum Genomics Société Anonyme Analysis

Updated on 10-09-2022
Price $3.08
Beta 1.019
Volume Avg. $91.95 thousand
Market Cap $84.24 M
52 Week Range $1.541 - $5.22

Quantum Genomics Société Anonyme opened the day at $3.08 which is -0.33 % on yesterday's close. Quantum Genomics Société Anonyme has a 52 week high of $5.22 and 52 week low of $1.541, which is a difference of $3.679. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $84.24 M and total net profit is $116211 which means the company is trading at 724.92 times profit to market capitalization. Theoretically, if you were to buy Quantum Genomics Société Anonyme for $84.24 M, it would take 15 years to get your money back. Quantum Genomics Société Anonyme are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Quantum Genomics Société Anonyme Stock Forecast - Is Quantum Genomics Société Anonyme a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreSell
DE ScoreNeutral
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value

PE Ratio -5.674
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing Quantum Genomics Société Anonyme

Price Book Value Ratio 4.803 Price To Book Ratio 4.803
Price To Sales Ratio 0.000 Price Earnings Ratio -5.674

How liquid is Quantum Genomics Société Anonyme

Current Ratio 2.858
Quick Ratio 1.812


Debt Ratio 0.487 Debt Equity Ratio 0.950
Long Term Debt To Capitalization 0.206 Total Debt To Capitalization 0.000

Latest news about Quantum Genomics Société Anonyme

About Quantum Genomics Société Anonyme

CEO : Mr. Lionel Segard
Sector : Healthcare
Industry : Biotechnology

Website :

Exchange : Paris

Description :

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.

My Newsletter

Sign Up For Updates & Newsletters